12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Prism Pharmaceuticals, Baxter deal

Baxter will acquire cardiovascular company Prism for $170 million in cash, plus up to $168 million in milestones. Baxter said Prism's lead product, Nexterone amiodarone, is a good addition to Baxter's portfolio of premix drugs...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >